News | May 04, 2024
Astec LifeSciences posts Q4FY24 consolidated loss at Rs. 97.39 lakhs
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Both organisations enter into a long- term collaboration to expand patient access in India
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
Subscribe To Our Newsletter & Stay Updated
